{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:07:23Z","timestamp":1784308043034,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006885","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T00:00:00Z","timestamp":1305072000000}}],"reference-count":172,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006885.pub2","type":"journal-article","created":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T12:51:23Z","timestamp":1305118283000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer"],"prefix":"10.1002","volume":"2011","author":[{"given":"Pan Feng","family":"Shang","sequence":"first","affiliation":[{"name":"Second Hospital of Lanzhou University; Department of Urology; No. 82, Cui Ying Men Street Lanzhou City Gansu China 730030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Kwong","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Department of Non-Communicable Disease Epidemiology; Keppel Street London UK WC1E 7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Second Hospital of Lanzhou University; Institute of Urology; No. 82, Cui Ying Men Street Lanzhou City Gansu China 730030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[{"name":"Lanzhou University; Evidence-Based Medicine Center, School of Basic Medical Sciences; No. 199, Donggang West Road Lanzhou City Gansu China 730000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Lanzhou University; Evidence-Based Medicine Center, School of Basic Medical Sciences; No. 199, Donggang West Road Lanzhou City Gansu China 730000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KeHu","family":"Yang","sequence":"additional","affiliation":[{"name":"Lanzhou University; Evidence-Based Medicine Center, School of Basic Medical Sciences; No. 199, Donggang West Road Lanzhou City Gansu China 730000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong Jin","family":"Yue","sequence":"additional","affiliation":[{"name":"Second Hospital of Lanzhou University; Department of Urology; No. 82, Cui Ying Men Street Lanzhou City Gansu China 730030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Qiang","family":"Tian","sequence":"additional","affiliation":[{"name":"Lanzhou University; Evidence-Based Medicine Center, School of Basic Medical Sciences; No. 199, Donggang West Road Lanzhou City Gansu China 730000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,11]]},"reference":[{"key":"10.1002\/14651858.CD006885.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-2042.2005.01064.x","article-title":"Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer","volume":"12","author":"Cheng","year":"2005","journal-title":"International Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8","article-title":"Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Gu\u00e9rin. A controlled prospective study on the prophylaxis of superficial bladder cancer","volume":"72","author":"Melekos","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02550957","article-title":"BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospect","volume":"28","author":"Melekos","year":"1996","journal-title":"International Urology and Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0004|cit4","first-page":"281","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus epirubicin in the prophylaxis of recurrent and\/or multiple superficial bladder tumours","volume":"53","author":"Melekos","year":"1996","journal-title":"Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Gu\u00e9rin, and Bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester","year":"2010","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","article-title":"Intravesical instillation of epirubicin, bacillus Calmette-Gu\u00e9rin and bacillus Calmette-Gu\u00e9rin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European organization for research and treatment of cancer genito-urinary group randomized phase III trial","volume":"166","author":"Meijden","year":"2001","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"Journal of clinical oncology"},{"issue":"4-5","key":"10.1002\/14651858.CD006885.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1078-1439(99)00015-0","article-title":"Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction","volume":"4","author":"Akaza","year":"1999","journal-title":"Urologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1464-410X.2003.04360.x","article-title":"Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index","volume":"92","author":"Ali-El-Dein","year":"2003","journal-title":"British Journal of Urology International"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)68555-2","article-title":"Sequential Bacillus Calmette-Gu\u00e9rin and epirubicin versus Bacillus Calmette-Gu\u00e9rin alone for superficial bladder tumors: a randomized prospective study","volume":"162","author":"Ali-El-Dein","year":"1999","journal-title":"The Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1098-2388(199709\/10)13:5<335::AID-SSU7>3.0.CO;2-E","article-title":"Treatment of superficial bladder cancer with intravesical chemotherapy","volume":"13","author":"Badalament","year":"1997","journal-title":"Seminars in Surgical Oncology"},{"issue":"4-5","key":"10.1002\/14651858.CD006885.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1078-1439(99)00011-3","article-title":"New treatment approaches for superficial and invasive bladder cancer","volume":"4","author":"Barton Grossman","year":"1999","journal-title":"Urologic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD006885.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/pros.20790","article-title":"Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?","volume":"68","author":"Beltrami","year":"2008","journal-title":"Prostate"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1442-2042.2000.00176.x","article-title":"Clinical experience with BCG alone versus BCG plus epirubicin","volume":"7","author":"Bilen","year":"2000","journal-title":"International Journal of Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006885.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/s00761-004-0664-9","article-title":"Adjuvant and neoadjuvant therapy of urinary bladder carcinoma","volume":"10","author":"Bismarck","year":"2004","journal-title":"Onkologe"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0016|cit16","first-page":"507","article-title":"Bacillus Calmette-Gu\u00e9rin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials: Editorial comment","volume":"31","author":"Bohle","year":"2005","journal-title":"International Brazilian Journal of Urology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00686931","article-title":"Superficial bladder cancer: State of the art","volume":"35 Suppl","author":"Bono","year":"1994","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0018|cit18","first-page":"229","article-title":"Stage T1 grade 3 bladder cancer: Treatment and prognostic factors","volume":"9","author":"Bono","year":"1995","journal-title":"Acta Urologica Italia"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000020171","article-title":"Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer","volume":"37","author":"Bono","year":"2000","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00001622-200305000-00009","article-title":"Bladder cancer","volume":"15","author":"Borden","year":"2003","journal-title":"Current Opinion in Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1464-410X.2002.02696.x","article-title":"Superficial bladder cancer T1G3: the choice of treatment","volume":"89","author":"Borkowski","year":"2002","journal-title":"British Journal of Urology International"},{"issue":"18","key":"10.1002\/14651858.CD006885.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"Mitomycin C: a clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treatment Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006885.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.6004\/jnccn.2006.0086","article-title":"Contemporary intravesical treatment options for urothelial carcinoma of the bladder","volume":"4","author":"Brassell","year":"2006","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0025|cit25","first-page":"131","article-title":"Immunotherapy with BCG in high risk recurrent bladder cancers previously treated with multiple cycles of chemotherapy: Long-term results","volume":"12","author":"Brausi","year":"1998","journal-title":"Acta Urologica Italica"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0027|cit27","first-page":"107","article-title":"Superficial bladder cancer epidemiology, diagnosis and management","volume":"53","author":"Bulbul","year":"2005","journal-title":"The Lebanese Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.juro.2008.03.038","article-title":"Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study","volume":"180","author":"Cai","year":"2008","journal-title":"The Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2003.12.014","article-title":"Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder","volume":"45","author":"Canda","year":"2004","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0030|cit30","first-page":"21","article-title":"Conservative treatment of high-risk (T1G3) transitional carcinoma","volume":"68","author":"Catanzaro","year":"1996","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0031|cit31","first-page":"317","article-title":"Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder","volume":"101","author":"Cervenakov","year":"2000","journal-title":"Bratislavsk\u00e9 Lek\u00e1rske Listy"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0032|cit32","first-page":"53","article-title":"Commentary on intravesical mitoxantrone versus recombinant interferon alfa after resection of Superficial bladder cancer","volume":"3","author":"Chung","year":"2005","journal-title":"American Journal of Urology Review"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000078798","article-title":"Standard versus hydrophilic catheterization in the adjuvant treatment of patients with superficial bladder cancer","volume":"73","author":"Cindolo","year":"2004","journal-title":"Urologia Internationalis"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.soc.2004.11.001","article-title":"Bladder cancer - resection\/ablation","volume":"14","author":"Corica","year":"2005","journal-title":"Surgical Oncology Clinics of North America"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ncpuro0784","article-title":"The management of superficial bladder cancer","volume":"4","author":"Dalbagni","year":"2007","journal-title":"Nature Clinical Practice. Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0036|cit36","first-page":"48","article-title":"Nonspecific immunotherapy with BCG vaccine in bladder tumors","volume":"43","author":"Damianov","year":"1990","journal-title":"Khirurgiia"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00001813-199406000-00006","article-title":"Combined immunochemotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors","volume":"53","author":"Damianov","year":"1994","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0038|cit38","first-page":"480","article-title":"Current insights in the treatment of superficial transitional cell carcinoma of the bladder","volume":"19","author":"Reijke","year":"1996","journal-title":"Onkologie"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer - Genito-Urinary Group Phase III Trial","volume":"173","author":"Reijke","year":"2005","journal-title":"The Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0040|cit40","first-page":"17","article-title":"Immunotherapy in superficial bladder cancer","volume":"3","author":"Reijke","year":"2005","journal-title":"Enhancer - Biotherapy of Cancer"},{"issue":"Suppl","key":"10.1002\/14651858.CD006885.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1007\/BF00262490","article-title":"Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overview","volume":"20","author":"Denis","year":"1987","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial","volume":"7","author":"Stasi","year":"2006","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ctrv.2005.04.006","article-title":"High-quality evidence in oncology from 21st October to 18th November 2004: A summary","volume":"31","author":"Djulbegovic","year":"2005","journal-title":"Cancer Treatment Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00761-005-0876-7","article-title":"Immunotherapy of urologic tumors","volume":"11","author":"Doehn","year":"2005","journal-title":"Onkologe"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0094-0143(05)70240-8","article-title":"An overview of the treatment of superficial bladder cancer: Intravesical chemotherapy","volume":"27","author":"Duque","year":"2000","journal-title":"The Urologic Clinics of North America"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10147-004-0457-6","article-title":"Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: A review of etiological features, natural history, and management","volume":"10","author":"El-Sebaie","year":"2005","journal-title":"International Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0048|cit48","first-page":"69","article-title":"Trial with bacillus Calmette-Guerin and epirubicin combination in the prophylaxis of superficial bladder cancer","volume":"52","author":"Erol","year":"1994","journal-title":"Urologia Internationalis"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00042307-199509000-00011","article-title":"Treatment of superficial bladder cancer","volume":"5","author":"Fradet","year":"1995","journal-title":"Current Opinion in Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.eururo.2006.05.035","article-title":"Improving efficacy of intravesical chemotherapy","volume":"50","author":"Gasi\u00f3n","year":"2006","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1211\/0022357021778268","article-title":"Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery","volume":"54","author":"Goldberg","year":"2002","journal-title":"The Journal of Pharmacy and Pharmacology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006885.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"v123","DOI":"10.1093\/annonc\/mdj966","article-title":"Actual experience and future development of gemcitabine in superficial bladder cancer","volume":"17","author":"Gontero","year":"2006","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00002371-200103000-00013","article-title":"Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1\/G1-2","volume":"24","author":"Grasso","year":"2001","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00120-006-1040-8","article-title":"Bladder carcer - What's new","volume":"45","author":"Gschwend","year":"2006","journal-title":"Der Urologe - Ausgabe A"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1586\/14737140.5.6.1023","article-title":"Recent advances in the treatment of bladder cancer","volume":"5","author":"Gwynn","year":"2005","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.cco.0000219258.75961.1a","article-title":"Bladder cancer","volume":"18","author":"Gwynn","year":"2006","journal-title":"Current Opinion in Oncology"},{"issue":"6933","key":"10.1002\/14651858.CD006885.pub2-BIB0057|cit57","first-page":"910","article-title":"Superficial bladder cancer","volume":"308","author":"Hall","year":"1994","journal-title":"British Medical Journal (Clinical research ed.)"},{"issue":"9","key":"10.1002\/14651858.CD006885.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1818::AID-CNCR25>3.0.CO;2-0","article-title":"Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function","volume":"86","author":"Hinotsu","year":"1999","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/14651858.CD006885.pub2-BIB0059|cit59","first-page":"677","article-title":"Effect of intravesical high dose epirubicin versus Bacillus Calmette-Gu\u00e9rin instillation on the recurrence and progression of superficial bladder cancer: A prospective, multicenter study","volume":"46","author":"Hong","year":"2005","journal-title":"The Korean Journal of Urology"},{"issue":"1B","key":"10.1002\/14651858.CD006885.pub2-BIB0060|cit60","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Research"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.COC.0000026911.98171.C6","article-title":"Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation","volume":"26","author":"Huncharek","year":"2003","journal-title":"American Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.coc.0000135570.37287.7f","article-title":"The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: A meta analytic comparison of chemotherapy versus bacilli Calmette-Gu\u00e9rin immunotherapy","volume":"27","author":"Huncharek","year":"2004","journal-title":"American Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1442-2042.2008.02239.x","article-title":"Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience","volume":"16","author":"Iida","year":"2009","journal-title":"International Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/14737140.7.4.567","article-title":"Superficial bladder cancer: part 2. Management","volume":"7","author":"Josephson","year":"2007","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"9","key":"10.1002\/14651858.CD006885.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1586\/14737140.6.9.1301","article-title":"Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer","volume":"6","author":"Kausch","year":"2006","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1442-2042.1999.06441.x","article-title":"Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy","volume":"6","author":"Kondo","year":"1999","journal-title":"International Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0067|cit67","first-page":"91","article-title":"The importance urinary glycosaminoglycan as a marker for superficial bladder tumors","volume":"15","author":"Konuko\u011flu","year":"1995","journal-title":"Cancer Biochemistry Biophysics"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1515\/JBCPP.1996.7.2.115","article-title":"Urinary zinc levels in patients with superficial bladder cancer","volume":"7","author":"Konuko\u011flu","year":"1996","journal-title":"Journal of Basic and Clinical Physiology and Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"The Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0970-1591.37614","article-title":"Carcinoma-in-situ bladder - An early indication for cystectomy?","volume":"18","author":"Kumar","year":"2002","journal-title":"Indian Journal of Urology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006885.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000052386","article-title":"Treatment of superficial bladder tumors: Achievements and needs","volume":"37","author":"Kurth","year":"2000","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0072|cit72","first-page":"93","article-title":"Bladder cancer","volume":"46","author":"Lamm","year":"1996","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4-5","key":"10.1002\/14651858.CD006885.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1999","journal-title":"Urologic Oncology"},{"issue":"6I","key":"10.1002\/14651858.CD006885.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1097\/01.ju.0000127757.72243.3e","article-title":"Management of bladder cancer","volume":"171","author":"Lamm","year":"2004","journal-title":"The Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0075|cit75","first-page":"323-6, 331-2","article-title":"Bladder cancer: current optimal intravesical treatment","volume":"25","author":"Lamm","year":"2005","journal-title":"Urologic Nursing"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.urolonc.2005.05.005","article-title":"Bladder cancer clinical trials","volume":"23","author":"Lerner","year":"2005","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/014107680109400305","article-title":"BCG immunotherapy for superficial bladder cancer","volume":"94","author":"Lockyer","year":"2001","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.urology.2003.12.023","article-title":"Effect of intravesical instillation on performance of uCYT+ test","volume":"63","author":"Lodde","year":"2004","journal-title":"Urology"},{"issue":"Suppl","key":"10.1002\/14651858.CD006885.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"iv85","DOI":"10.1093\/annonc\/mdi914","article-title":"Systemic chemotherapy for patients with advanced and metastatic bladder cancer: Current status and future directions","volume":"16","author":"Lorusso","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m P Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience European Urology 2000 16 20","DOI":"10.1159\/000052377"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1040-8428(03)00075-1","article-title":"Intravesical therapy of superficial bladder cancer","volume":"47","author":"Malmstr\u00f6m","year":"2003","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1586\/14737140.4.6.1057","article-title":"Advances in intravesical therapy of urinary bladder cancer","volume":"4","author":"Malmstr\u00f6m","year":"2004","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1014492517088","article-title":"Current problems and needs in the treatment of pT1 G3 bladder carcinoma","volume":"33","author":"Martinez Portillo","year":"2001","journal-title":"International Urology and Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1464-410X.1996.00135.x","article-title":"The management of superficial bladder cancer: An interactive seminar","volume":"78","author":"McFarlane","year":"1996","journal-title":"British Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.ju.0000169425.93927.7a","article-title":"Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906)","volume":"174","author":"Mehraban","year":"2005","journal-title":"The Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/1381612003401019","article-title":"Intravesical therapy of superficial bladder cancer","volume":"6","author":"Melekos","year":"2000","journal-title":"Current Pharmaceutical Design"},{"issue":"Suppl","key":"10.1002\/14651858.CD006885.pub2-BIB0087|cit87","first-page":"545","article-title":"Preliminary results of a randomized phase-II-study BCG vs epirubicin as intravesical prophylaxis of urothelial bladder tumors","volume":"116","author":"Merkle","year":"1990","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0088|cit88","first-page":"611","article-title":"Novel insights into the mechanism of action of intravesical immunomodulators","volume":"19","author":"Mitropoulos","year":"2005","journal-title":"In Vivo (Athens, Greece)"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0749-0690(18)30121-6","article-title":"Genitourinary cancers in older adults","volume":"14","author":"Morganstern","year":"1998","journal-title":"Clinics in Geriatric Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1383\/surg.2006.24.5.181","article-title":"Bladder cancer","volume":"24","author":"Munro","year":"2006","journal-title":"Surgery (Oxford)"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000052521","article-title":"The use of valrubicin for the chemoresection of superficial bladder cancer - A marker lesion study","volume":"39","author":"Newling","year":"2001","journal-title":"European Urology"},{"issue":"2-3","key":"10.1002\/14651858.CD006885.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/02841860151116466","article-title":"A systematic overview of chemotherapy effects in urothelial bladder cancer","volume":"40","author":"Nilsson","year":"2001","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14737140.3.6.809","article-title":"Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer","volume":"3","author":"O'Donnell","year":"2003","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"7","key":"10.1002\/14651858.CD006885.pub2-BIB0094|cit94","first-page":"714","article-title":"Toxicity of prophylaxis of superficial bladder tumors","volume":"18","author":"Ojea Calvo","year":"1994","journal-title":"Actas Urologicas Espa\u0148olas"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1464-410X.2005.05711.x","article-title":"Is intravesical chemotherapy for superficial bladder cancer still justified?","volume":"96","author":"Okeke","year":"2005","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002512-199915040-00006","article-title":"Epirubicin: a review of its intravesical use in superficial bladder cancer","volume":"15","author":"Onrust","year":"1999","journal-title":"Drugs & Aging"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000049828","article-title":"Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions","volume":"40","author":"Oosterlinck","year":"2001","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1464-410x.2001.00948.x","article-title":"The management of superficial bladder cancer","volume":"87","author":"Oosterlinck","year":"2001","journal-title":"BJU International"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0099|cit99","first-page":"65","article-title":"Guidelines on diagnosis and treatment of superficial bladder cancer","volume":"56","author":"Oosterlinck","year":"2004","journal-title":"Minerva Urologica e Nefrologica"},{"issue":"6 suppl 1","key":"10.1002\/14651858.CD006885.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.urology.2005.07.063","article-title":"Low-grade Ta (noninvasive) urothelial carcinoma of the bladder","volume":"66","author":"Oosterlinck","year":"2005","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00001622-199405000-00015","article-title":"Transitional cell carcinoma of the bladder","volume":"6","author":"Ozen","year":"1994","journal-title":"Current Opinion in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0102|cit102","first-page":"53","article-title":"Review of metastatic bladder cancer","volume":"58","author":"Pagliaro","year":"2006","journal-title":"Minerva Urologica e Nefrologica"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00042307-200309000-00002","article-title":"The current status of intravesical therapy for superficial bladder cancer","volume":"13","author":"Patard","year":"2003","journal-title":"Current Opinion in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1120009X.1993.11739234","article-title":"Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin","volume":"5","author":"Pavone-Macaluso","year":"1993","journal-title":"Journal of Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0105|cit105","first-page":"35","article-title":"T1G3 bladder tumors: 5 years later","volume":"68","author":"Pegoraro","year":"1996","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urology.2004.04.026","article-title":"Current and new strategies in immunotherapy for superficial bladder cancer","volume":"64","author":"Perabo","year":"2004","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0107|cit107","first-page":"147","article-title":"High-risk superficial bladder cancer: Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder","volume":"15","author":"Pham","year":"1997","journal-title":"Seminars in Urologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0108|cit108","first-page":"111","article-title":"The cost of treatment and follow-up of bladder cancer in Italy","volume":"79","author":"Racioppi","year":"2007","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000049810","article-title":"Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test","volume":"40","author":"Raitanen","year":"2001","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0110|cit110","first-page":"25","article-title":"Transitional carcinoma of the bladder at the T1G3 stage: personal experience","volume":"68","author":"Roggia","year":"1996","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0111|cit111","first-page":"317","article-title":"Results of local treatment of superficial bladder cancer patients with BCG versus interferon versus interferon + epirubicin. Multicentric, randomized, prospective study (preliminary report)","volume":"8","author":"Romics","year":"1996","journal-title":"Magyar Urologia"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00063030-200216050-00004","article-title":"Potential of interferon-\u03b1 in solid tumours: Part 2","volume":"16","author":"Santhanam","year":"2002","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0022-5347(17)32794-5","article-title":"Principles of oncology and immunology, and tumors of bladder, penis and urethra","volume":"152","author":"Scher","year":"1994","journal-title":"The Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0090-4295(96)00007-6","article-title":"Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder","volume":"47","author":"Serretta","year":"1996","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Shelley","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley","year":"2010","journal-title":"Cancer treatment reviews"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ncpuro0762","article-title":"Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer?","volume":"4","author":"Skinner","year":"2007","journal-title":"Nature Clinical Practice. Urology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/jcb.240501323","article-title":"Superficial bladder cancer: diagnosis, surveillance and treatment","volume":"161","author":"Soloway","year":"1992","journal-title":"Journal of Cellular Biochemistry. Supplement"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0119|cit119","first-page":"212","article-title":"Editorial comment","volume":"31","author":"Soloway","year":"2005","journal-title":"International Brazilian Journal of Urology"},{"issue":"9","key":"10.1002\/14651858.CD006885.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2298\/VSP0709629S","article-title":"Superficial urinary bladder tumors treatment results--a 10-year experience","volume":"64","author":"Stankovi\u0107","year":"2007","journal-title":"Vojnosanit Pregl"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"The Journal of Urology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD006885.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.juro.2008.09.053","article-title":"Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study","volume":"181","author":"Sylvester","year":"2009","journal-title":"The Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0125|cit125","first-page":"263","article-title":"Intra-arterial chemotherapy for muscle-invasive urinary bladder cancer","volume":"42","author":"Takahashi","year":"1996","journal-title":"Hinyokika Kiyo. Acta Urologica Japonica"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000030495","article-title":"Cytological changes induced by intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"64","author":"Takashi","year":"2000","journal-title":"Urologia Internationalis"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0127|cit127","first-page":"215","article-title":"Conservative treatment of high grade superficial bladder tumours","volume":"77","author":"Trinchieri","year":"2005","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0128|cit128","first-page":"51","article-title":"Prophylactic intravesical instillation therapy with mitomycin-C and adriamycin for recurrent superficial bladder cancer","volume":"65","author":"Tsujikawa","year":"2003","journal-title":"Nishinihon Journal of Urology"},{"issue":"Suppl","key":"10.1002\/14651858.CD006885.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/BF00686923","article-title":"The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report","volume":"35","author":"Uekado","year":"1994","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1570-9124(03)00020-5","article-title":"Intravesical chemotherapy: An update - New trends and perspectives","volume":"1","author":"Heijden","year":"2003","journal-title":"EAU Update Series"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0131|cit131","first-page":"67","article-title":"New treatments for superficial bladder cancer","volume":"11","author":"Heijden","year":"2003","journal-title":"Nederlands Tijdschrift voor Urologie"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD006885.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.juro.2006.06.007","article-title":"Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response","volume":"176","author":"Heijden","year":"2006","journal-title":"The Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1464-410X.1996.09002.x","article-title":"Phase II trials in Ta, T1 bladder cancer. The marker tumour concept","volume":"77","author":"Meijden","year":"1996","journal-title":"British Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006885.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European Organization for Research and Treatment of Cancer trials","volume":"164","author":"Meijden","year":"2000","journal-title":"The Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2005.05.011","article-title":"EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ","volume":"48","author":"Meijden","year":"2005","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eursup.2004.02.012","article-title":"Treatment of superficial bladder cancer: A discussion on intravesical immunotherapy and intravesical chemotherapy","volume":"3","author":"Whelan","year":"2004","journal-title":"European Urology Supplements"},{"issue":"8","key":"10.1002\/14651858.CD006885.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.eursup.2007.01.028","article-title":"The Treatment of Non-Muscle-Invasive Bladder Cancer with Intravesical Chemotherapy and Immunotherapy","volume":"6","author":"Whelan","year":"2007","journal-title":"European Urology Supplements"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003495-199753030-00005","article-title":"Current recommendations for the management of bladder cancer. Drug therapy","volume":"53","author":"Witjes","year":"1997","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0090-4295(00)00572-0","article-title":"Management of superficial bladder cancer with intravesical chemotherapy: An update","volume":"56","author":"Witjes","year":"2000","journal-title":"Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","article-title":"Intravesical gemcitabine: a phase 1 and pharmacokinetic study","volume":"45","author":"Witjes","year":"2004","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ncpuro0009","article-title":"Intravesical chemotherapy for superficial bladder cancer","volume":"1","author":"Witjes","year":"2004","journal-title":"Nature Clinical Practice. Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2007.08.015","article-title":"Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results","volume":"53","author":"Witjes","year":"2008","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/aje\/kwk047","article-title":"A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke","volume":"165","author":"Alberg","year":"2007","journal-title":"American Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD006885.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials: the CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000472938","article-title":"Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors","volume":"14","author":"Calais da Silva","year":"1988","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1986.4.3.425","article-title":"Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue","volume":"4","author":"Cersosimo","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000474798","article-title":"4'epidoxirubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer","volume":"21","author":"Silva","year":"1992","journal-title":"European Urology"},{"issue":"6964","key":"10.1002\/14651858.CD006885.pub2-BIB0148|cit148","first-page":"1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0149|cit149","unstructured":"Ray ER O'Brien TS Aproaches to reducing recurrence in superficial bladder cancer Business briefing: European kidney and urological disease 2006 1 6"},{"issue":"Suppl","key":"10.1002\/14651858.CD006885.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1007\/BF00686919","article-title":"Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group","volume":"35","author":"Eto","year":"1994","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0151|cit151","unstructured":"Ferlay J Bray F Pisani P Parkin DM GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5 2004"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF02201977","article-title":"Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients","volume":"15","author":"Herr","year":"1997","journal-title":"World Journal of Urology"},{"issue":"7414","key":"10.1002\/14651858.CD006885.pub2-BIB0153|cit153","first-page":"557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal (Clinical research ed.)"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0154|cit154","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 http:\/\/www.cochrane-handbook.org\/ (accessed 9 February 2011) updated September 2009"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/030089160709300102","article-title":"Risk factors for bladder cancer","volume":"93","author":"Jankovi\u0107","year":"2007","journal-title":"Tumori"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-4295(99)00463-X","article-title":"Intravesical therapy for bladder cancer","volume":"55","author":"Kamat","year":"2000","journal-title":"Urology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.ju.0000100386.07370.0a","article-title":"A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta\/T1 transitional cell carcinoma of the bladder","volume":"171","author":"Koga","year":"2004","journal-title":"The Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD006885.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)67973-6","article-title":"Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations","volume":"163","author":"Lebret","year":"2000","journal-title":"The Journal of Urology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0159|cit159","unstructured":"Lefebvre C McDonald S Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE Fourth International Cochrane Colloquium, Adelaide Australia, 20-24 October 1996"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0022-5347(17)53725-8","article-title":"Prognostic parameters in superficial bladder cancer: an analysis of 315 cases","volume":"127","author":"Lutzeyer","year":"1982","journal-title":"The Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006885.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1464-410X.2004.04884.x","article-title":"Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection","volume":"94","author":"Mitsumori","year":"2004","journal-title":"BJU international"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"The Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1078-1439(01)00153-3","article-title":"Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder","volume":"7","author":"Morgan","year":"2002","journal-title":"Urologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","article-title":"Bacillus Calmette-Gu\u00e9rin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells","volume":"14","author":"Naoe","year":"2007","journal-title":"International Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"European Urology"},{"issue":"35","key":"10.1002\/14651858.CD006885.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2006.08.5431","article-title":"Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments","volume":"24","author":"Parekh","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0167|cit167","volume-title":"Cancer incidence in five continents","author":"Parkin","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD006885.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1464-410X.1994.tb16585.x","article-title":"Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin","volume":"74","author":"Popert","year":"1994","journal-title":"British Journal of Urology"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0169|cit169","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"4","key":"10.1002\/14651858.CD006885.pub2-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001986","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin in Ta and T1 bladder cancer","author":"Shelley","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006885.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1100\/tsw.2006.403","article-title":"Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer","volume":"9","author":"Meijden","year":"2006","journal-title":"TheScientificWorldJournal"},{"key":"10.1002\/14651858.CD006885.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bjmsu.2010.02.008","article-title":"A comparison of two BCG instillation regimens for non-muscle invasive bladder cancer: A retrospective cohort analysis of side effect profiles","volume":"3","author":"Wilson","year":"2010","journal-title":"British Journal of Medical and Surgical Urology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006885.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:32:14Z","timestamp":1784305934000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006885.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,5,11]]},"references-count":172,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006885.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,11]]}}}